Rafael Holdings, Inc., (NYSE American: RFL) changed 0.61% to recent value of $16.6. The stock transacted 12139 shares during most recent day however it has an average volume of 24.17K shares. It spotted trading -16.71% off 52-week high price. On the other end, the stock has been noted 140.58% away from the low price over the last 52-weeks.
Rafael Holdings, Inc., (NYSE American: RFL), reported revenue of $1.4 million and a loss per share of $0.07 for the third quarter of its 2019 fiscal year, the three months ended April 30, 2019.
Rafael Pharma announced that its lead compound, CPI-613® (devimistat), will be explored in a new combination for the treatment of T-cell lymphoma as a part of Stand Up To Cancer’s T-Cell Lymphoma Dream Team Research Grant.
Rafael Pharma’s Phase 2 trial of CPI-613 (devimistat) for patients with relapsed or refractory Burkitt lymphoma opened in multiple sites. The US FDA has designated devimistat orphan drug status for the treatment of Burkitt lymphoma.
Rafael Pharma’s Phase 3 pivotal trials of CPI-613 (devimistat) devimistat for patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia was ongoing in multiple sites.
Rafael Pharma completed its Phase 1 study of CPI-613 (devimistat) in combination with bendamustine in patients with relapsed or refractory T-cell lymphoma.
To meet the growing demands of its expanded clinical trial program, Rafael Pharma added a second qualified CPI-613 (devimistat) manufacturer and continued to build out its management team.
Remarks by Howard Jonas, Chairman and CEO of Rafael Holdings
“Rafael Holdings is supporting Rafael Pharma and Lipomedix as they pursue their clinical development programs including Rafael Pharma’s Phase 3 global trials of CPI-613. We are also continuing to make progress in our effort to realize the full value of our real estate holdings and particularly our 20-story commercial property and associated garage in Newark, New Jersey.”
RFL has profit margin remained -73.50% for the last 12 months.
The company has 13.56M of outstanding shares and 10.83M shares were floated in the market. According to the most recent quarter its current ratio was 13 that represents company’s ability to meet its current financial obligations. The price moved ahead of 4.04% from the mean of 20 days, 10.27% from mean of 50 days SMA and performed 38.73% from mean of 200 days price. Company’s performance for the week was 3.11%, 3.94% for month and YTD performance remained 109.33%.
Category – Earnings
Erichthonius Petralias says that his huge experience in 8 years, gives him priority among others. He worked for different national and international companies. He has unique insights into the investments for oil and gas field. He likes to share his predictions and analysis with readers. He still creates profitable equity portfolios for his clients.
Erichthonius has worked as an auditor for many years but is currently working as a business journalist so that he can work remotely and travel with his wife while she works as a travel nurse for several years. Erichthonius specializes in stock, gas and oil investments, dividends. He is a well-known person in business world.
Email: [email protected]